Artificial intelligence (AI) company Acryl (CEO Park Oe-jin) announced on the 31st that it participated in the HIMSS 2024 Europe Health Conference & Exhibition (hereinafter referred to as HIMSS Europe 2024) held at La Nuvola (Roma Convention Center) in Rome, Italy for three days from May 29th to 31st.
HIMSS Europe 2024 is the world's largest medical IT technology event hosted by the Healthcare Information and Management Systems Society (HIMSS) in the United States. HIMSS is the most influential organization in the medical information field with over 120,000 members from over 100 countries around the world, and this event is known as a place where over 30,000 medical professionals and ICT company officials from around the world participate every year to share the latest technology trends and business information.
At this event, Acryl Co., Ltd. focused on introducing Esther Deprex (depression diagnosis assistance) and Esther Prostex 1, 2 (differential diagnosis/prognosis prediction of prostatic hyperplasia) developed through the Doctor Answer 2.0 project hosted by the Ministry of Science and ICT and the National IT Industry Promotion Agency (NIPA). The exhibition booth demonstrated the developed products and announced the development results.
Esther Deprex is designed to assist in the diagnosis of depression by digitizing and quantifying interview records between doctors and patients, learning them, and then analyzing information related to the patient's emotional and psychiatric conditions with AI to assist in the diagnosis of depression. It is expected to be utilized as an objective and efficient diagnostic assistance tool for medical professionals.
Esther Prostex 1 is designed to assist in the differential diagnosis of prostatic hyperplasia by analyzing the causes of various lower urinary tract symptoms that are difficult to distinguish, replacing existing invasive tests. It analyzes the results of general tests that have already been performed with AI to assist in the diagnosis of prostatic hyperplasia. This is expected to have effects such as reducing medical costs required for performing invasive tests.
Esther Prostex 2 is designed to predict the prognosis of patients with prostatic hyperplasia and predicts the treatment effect after drug administration based on the patient's clinical information. This can be expected to increase the effectiveness of drug treatment, predict improvement in urinary disorders, and manage treatment for surgical candidates.
These products are currently undergoing or preparing for clinical trials in Korea.
Based on the achievements and know-how achieved in Korea, Acryl Co., Ltd. has discussed cooperation with various domestic and international organizations, including global companies and medical institutions. Through this event, it plans to showcase its excellent artificial intelligence analysis technology and digital healthcare technology to the European market and expand business partnerships and conduct marketing activities for its future entry into Europe.
Acryl Co., Ltd. was founded in 2011 and developed Korea's first multimodal emotional AI, and is leading the 'wellcare', a healthcare-centered convergence industry, based on references in the finance/insurance/media/public sectors and expertise and success in the healthcare AI field. In addition, we have been actively entering the healthcare market by developing medical AI together with various hospitals and institutions since 2018.